iGEM 2005: Synthetic Biology’s Future



Cambridge, Mass. – Before plunging too deeply into iGEM 2005 – the intercollegiate Genetically Engineered Machine competition, held at MIT last weekend, consider a few of the awards: Best Use of Transmogrified Smiley Faces (Caltech), Best Confession (U Texas), Most Modest Goal (MIT), Best Uniform (University of Cambridge, U.K.) My favorite was Best “Hail Mary” Cloning (Oklahoma).

Teams from 13 colleges, comprised mostly of undergraduates, worked over the summer towards the not-so-modest goal of “designing and building the ‘coolest’ systems from standard, interchangeable biological parts and to operate those systems in living cells.” There were digital decoders, light-controlled gene expression techniques, bacterial relay races, a bacterial sketch pad, and of course, transmogrified smiley faces. Students used genetic engineering to coax bacteria to perform a wide variety of tasks.

 

2005 iGEM
Teams:

 
 

Princeton
Oklahoma
ETH Zurich
MIT
Caltech
U. Toronto
U Cambridge
Texas U
Penn State
UC Berkeley
Davidson
Harvard
UCSF

 
That many projects didn’t work quite as planned misses the point, explains iGEM coordinator Randy Rettberg, a principal research engineer in biological engineering division at MIT and director of the Registry of Standard Biological Parts at MIT. Following presentations by all the teams on Saturday, Rettberg told the young bioengineers, “Without your optimism, you’d be stopped early.” 

These students, suggests Rettberg, are internalizing the notion that biology can be marshaled to perform almost anything that mechanical or electronic systems can do. They are also building the parts to tackle those tasks. “Most of the parts in the registry have been contributed by students,” he says.

Rettberg is staunch evangelist for synthetic biology, and came to MIT by a somewhat circuitous route. An engineer by training, he worked for years at Internet pioneer BBN (now Genuity), later moved to Sun Microsystems, where he was CTO for storage systems, and came to MIT just a few years ago.

“I believe learning something brand new is entirely refreshing,” says Rettberg. Encouraged by prominent MIT researcher Tom Knight, Rettberg dove into biology and bioengineering. He has big hopes for iGEM.

Last year, just five schools – MIT, Caltech, Boston University (with participation from Harvard), Princeton, and the University of Texas, Austin, competed. Response mushroomed this year. “Fifty students applied for the University of Cambridge team of six. I count that as 44 disappointed students,” he says.

Indeed, rather than rank winners hierarchically, Rettberg and the other judges made 50 or so awards. Student teams worked on their projects throughout the summer, and several are continuing in efforts to complete their projects. Next year Rettberg expects 30 to 50 schools to compete and he’s scanning the horizon for funding sources.

Related links:

iGEM

Synthetic Biology: The Real Thing

Real Promise for Synthetic Biology

It's a Bug's Life

 

  

 

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .